Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Change in Accured Expenses (2021 - 2026)

MoonLake Immunotherapeutics' Change in Accured Expenses history spans 6 years, with the latest figure at $7.1 million for Q1 2026.

  • Quarterly Change in Accured Expenses rose 557.78% to $7.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $11.3 million through Mar 2026, up 75.55% year-over-year, with the annual reading at $2.6 million for FY2025, 49.87% down from the prior year.
  • Change in Accured Expenses came in at $7.1 million for Q1 2026, up from -$6.9 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $12.9 million in Q3 2025 to a low of -$6.9 million in Q4 2025.
  • The 5-year median for Change in Accured Expenses is $1.4 million (2023), against an average of $1.0 million.
  • Year-over-year, Change in Accured Expenses crashed 18799.85% in 2022 and then skyrocketed 557.78% in 2026.
  • MoonLake Immunotherapeutics' Change in Accured Expenses stood at $2.2 million in 2022, then rose by 28.06% to $2.9 million in 2023, then surged by 45.51% to $4.2 million in 2024, then tumbled by 265.24% to -$6.9 million in 2025, then surged by 203.28% to $7.1 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Change in Accured Expenses are $7.1 million (Q1 2026), -$6.9 million (Q4 2025), and $12.9 million (Q3 2025).